Clinical Trial Update: Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial at University Hospital Heidelberg is evaluating third-generation CD19-directed CAR T cells in relapsed or refractory CD19+ lymphoid d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma

Snippet

Sponsor: University Hospital Heidelberg | Conditions: Acute Lymphoblastic Leukemia, Adult, Acute Lymphoblastic Leukemia, Pediatric | Phase 1, Phase 2 | Status: RECRUITING